To amend title 35, United States Code, to prevent double patenting, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To amend title 35, United States Code, to prevent double patenting, and for other purposes., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Trade, Government Operations.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section H5438A902D3A04177BC8D18E57D57B9A8: 1. Short title This Act may be cited as the Stopping Pharma’s Ripoffs and Drug Savings For All Act.
- Section HE432E3EE15F049C9950231473A137384: 2. Prevention of double patenting Section 253 of title 35, United States Code, is amended by adding at the end the following: Except as provided in paragraph...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To amend title 35, United States Code, to prevent double patenting, and for other purposes., changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Trade, Government Operations
Primary Purpose
This bill, To amend title 35, United States Code, to prevent double patenting, and for other purposes., changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
IntroducedMr. Ryan introduced the following bill; which was referred to …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary_of_commerce"
- → Secretary of Commerce
Key Definitions
Terms defined in this bill
the United States Patent and Trademark Office
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology